Emilie Artru
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Emilie Artru has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Alexandra Masson-Lecomte
Saint-Louis Hospital 1 Hemato-Immunology Research Department, CEA, DRF-Francois Jacob Institute Paris, France
8 shared publications - Alix Jacquier
Saint-Louis Hospital 1 Hemato-Immunology Research Department, CEA, DRF-Francois Jacob Institute Paris, France
8 shared publications - Clément Dumont
Department of Medical Oncology, Hôpital Saint Louis, AP-HP, Paris, France
8 shared publications - Dzenis Koca
INSERM 4 Interdisciplinary Research Institute of Grenoble, IRIG-Biosanté, University Grenoble Alpes, CEA UMR 1292, Grenoble, France
8 shared publications - Edgardo D. Carosella
Saint-Louis Hospital 1 Hemato-Immunology Research Department, CEA, DRF-Francois Jacob Institute Paris, France
8 shared publications - Fatiha Bouhidel
Saint-Louis Hospital 5 Department of Pathology AP-HP.Nord - Université Paris Cité, Paris, France
8 shared publications
Latest Publications
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from ILT2 Identifies an Unexploited Pool of Intratumoral CD8+ Bystander T Cells with TCR-Independent Cytotoxicity in Renal Cell Carcinoma
Fig. S3. Transcriptomic characterization of the CD8+ILT2+ T cell subset
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from ILT2 Identifies an Unexploited Pool of Intratumoral CD8+ Bystander T Cells with TCR-Independent Cytotoxicity in Renal Cell Carcinoma
Fig. S3. Transcriptomic characterization of the CD8+ILT2+ T cell subset
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from ILT2 Identifies an Unexploited Pool of Intratumoral CD8+ Bystander T Cells with TCR-Independent Cytotoxicity in Renal Cell Carcinoma
Fig. S2. Quantitative analysis of spectral flow cytometry clusters.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from ILT2 Identifies an Unexploited Pool of Intratumoral CD8+ Bystander T Cells with TCR-Independent Cytotoxicity in Renal Cell Carcinoma
Fig. S2. Quantitative analysis of spectral flow cytometry clusters.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from ILT2 Identifies an Unexploited Pool of Intratumoral CD8+ Bystander T Cells with TCR-Independent Cytotoxicity in Renal Cell Carcinoma
Fig. S5. CD8+ILT2+ T cells display TCR-independent cytotoxicity selectively toward NKG2D ligand-expressing target cells.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from ILT2 Identifies an Unexploited Pool of Intratumoral CD8+ Bystander T Cells with TCR-Independent Cytotoxicity in Renal Cell Carcinoma
Fig. S5. CD8+ILT2+ T cells display TCR-independent cytotoxicity selectively toward NKG2D ligand-expressing target cells.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from ILT2 Identifies an Unexploited Pool of Intratumoral CD8+ Bystander T Cells with TCR-Independent Cytotoxicity in Renal Cell Carcinoma
Fig. S4. CD8+ILT2− T cells do not exhibit TCR-independent cytotoxic potential.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from ILT2 Identifies an Unexploited Pool of Intratumoral CD8+ Bystander T Cells with TCR-Independent Cytotoxicity in Renal Cell Carcinoma
Fig. S4. CD8+ILT2− T cells do not exhibit TCR-independent cytotoxic potential.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from ILT2 Identifies an Unexploited Pool of Intratumoral CD8+ Bystander T Cells with TCR-Independent Cytotoxicity in Renal Cell Carcinoma
Fig. S1. Association of the HLA-G/ILT2 and PD-L1/PD1 checkpoints with clinical parameters in ccRCC.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from ILT2 Identifies an Unexploited Pool of Intratumoral CD8+ Bystander T Cells with TCR-Independent Cytotoxicity in Renal Cell Carcinoma
Fig. S1. Association of the HLA-G/ILT2 and PD-L1/PD1 checkpoints with clinical parameters in ccRCC.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Data from ILT2 Identifies an Unexploited Pool of Intratumoral CD8+ Bystander T Cells with TCR-Independent Cytotoxicity in Renal Cell Carcinoma
Immune checkpoint inhibitors (ICI) have improved clear-cell renal cell carcinoma (ccRCC) therapy, yet many patients remain unresponsive. Alternative strategies are needed, and the HLA-G/ILT2 axis has emerged as a promising immunosuppressive pathway. In this study, we deeply characterized CD8+ILT2+ tumor-infiltrating lymphocytes (TIL) as a distinct subset from CD8+PD-1+ TILs in ccRCC, using high-dimensional spectral flow cytometry, single-cell transcriptomics, and T-cell receptor (TCR) clonotype analysis. CD8+ILT2+ TILs were terminally differentiated, highly cytotoxic “bystander” cells, enriched for virus-specific TCRs. They phenotypically, transcriptionally, and functionally mirrored their circulating counterparts, suggesting peripheral recruitment. In dynamic coculture assays, they exhibited potent TCR-independent cytotoxicity, mediated by activating innate receptors, namely NKG2D. However, HLA-G inhibited this activity, underscoring the immune-evasive role of the HLA-G/ILT2 axis. Our study defines CD8+ILT2+ TILs as an untapped effector population with potential antitumor activity and a promising therapeutic target in ccRCC. These findings offer new insights into TIL functional diversity and pave the way for innovative immunotherapies beyond conventional ICIs.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from ILT2 Identifies an Unexploited Pool of Intratumoral CD8+ Bystander T Cells with TCR-Independent Cytotoxicity in Renal Cell Carcinoma
Immune checkpoint inhibitors (ICI) have improved clear-cell renal cell carcinoma (ccRCC) therapy, yet many patients remain unresponsive. Alternative strategies are needed, and the HLA-G/ILT2 axis has emerged as a promising immunosuppressive pathway. In this study, we deeply characterized CD8+ILT2+ tumor-infiltrating lymphocytes (TIL) as a distinct subset from CD8+PD-1+ TILs in ccRCC, using high-dimensional spectral flow cytometry, single-cell transcriptomics, and T-cell receptor (TCR) clonotype analysis. CD8+ILT2+ TILs were terminally differentiated, highly cytotoxic “bystander” cells, enriched for virus-specific TCRs. They phenotypically, transcriptionally, and functionally mirrored their circulating counterparts, suggesting peripheral recruitment. In dynamic coculture assays, they exhibited potent TCR-independent cytotoxicity, mediated by activating innate receptors, namely NKG2D. However, HLA-G inhibited this activity, underscoring the immune-evasive role of the HLA-G/ILT2 axis. Our study defines CD8+ILT2+ TILs as an untapped effector population with potential antitumor activity and a promising therapeutic target in ccRCC. These findings offer new insights into TIL functional diversity and pave the way for innovative immunotherapies beyond conventional ICIs.
- 8 July 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 14 (8) , OF1-OF16
ILT2 Identifies an Unexploited Pool of Intratumoral CD8+ Bystander T Cells with TCR-Independent Cytotoxicity in Renal Cell Carcinoma
Immune checkpoint inhibitors (ICI) have improved clear-cell renal cell carcinoma (ccRCC) therapy, yet many patients remain unresponsive. Alternative strategies are needed, and the HLA-G/ILT2 axis has emerged as a promising immunosuppressive pathway. In this study, we deeply characterized CD8+ILT2+ tumor-infiltrating lymphocytes (TIL) as a distinct subset from CD8+PD-1+ TILs in ccRCC, using high-dimensional spectral flow cytometry, single-cell transcriptomics, and T-cell receptor (TCR) clonotype analysis. CD8+ILT2+ TILs were terminally differentiated, highly cytotoxic “bystander” cells, enriched for virus-specific TCRs. They phenotypically, transcriptionally, and functionally mirrored their circulating counterparts, suggesting peripheral recruitment. In dynamic coculture assays, they exhibited potent TCR-independent cytotoxicity, mediated by activating innate receptors, namely NKG2D. However, HLA-G inhibited this activity, underscoring the immune-evasive role of the HLA-G/ILT2 axis. Our study defines CD8+ILT2+ TILs as an untapped effector population with potential antitumor activity and a promising therapeutic target in ccRCC. These findings offer new insights into TIL functional diversity and pave the way for innovative immunotherapies beyond conventional ICIs.
- 8 July 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 14 (8) , OF1-OF16
ILT2 Identifies an Unexploited Pool of Intratumoral CD8+ Bystander T Cells with TCR-Independent Cytotoxicity in Renal Cell Carcinoma
Immune checkpoint inhibitors (ICI) have improved clear-cell renal cell carcinoma (ccRCC) therapy, yet many patients remain unresponsive. Alternative strategies are needed, and the HLA-G/ILT2 axis has emerged as a promising immunosuppressive pathway. In this study, we deeply characterized CD8+ILT2+ tumor-infiltrating lymphocytes (TIL) as a distinct subset from CD8+PD-1+ TILs in ccRCC, using high-dimensional spectral flow cytometry, single-cell transcriptomics, and T-cell receptor (TCR) clonotype analysis. CD8+ILT2+ TILs were terminally differentiated, highly cytotoxic “bystander” cells, enriched for virus-specific TCRs. They phenotypically, transcriptionally, and functionally mirrored their circulating counterparts, suggesting peripheral recruitment. In dynamic coculture assays, they exhibited potent TCR-independent cytotoxicity, mediated by activating innate receptors, namely NKG2D. However, HLA-G inhibited this activity, underscoring the immune-evasive role of the HLA-G/ILT2 axis. Our study defines CD8+ILT2+ TILs as an untapped effector population with potential antitumor activity and a promising therapeutic target in ccRCC. These findings offer new insights into TIL functional diversity and pave the way for innovative immunotherapies beyond conventional ICIs.